| Features: |
| Irinotecan is a chemotherapy drug widely used to treat several solid tumors. It is a semisynthetic camptothecin derivative and functions primarily as a topoisomerase I inhibitor. -Active metabolite: SN-38 (much more potent than irinotecan itself) Common Regimens Regimen Components FOLFIRI Folinic acid + 5-FU + Irinotecan FOLFIRINOX 5-FU + Leucovorin + Irinotecan + Oxaliplatin XELIRI / CAPIRI Capecitabine + Irinotecan Potential strategies to sensitize tumors to irinotecan: Strategy Rationale GSH depletion Reduces detox of SN-38 PRDX/TXNRD stress Lowers redox buffering Glycolysis inhibition Limits repair energy PEMF / AgNPs ↑ ROS, ↑ drug uptake Timing selenium Avoid boosting antioxidant defenses during therapyReport of combining CPT-11 and SeNPs to increase NRF2 in normal cells(chemoprotective) and decrease NRF2 in cancer cells(chemosentization). |
| Source: |
| Type: |
| Normal cells grow and divide in a regulated manner through the cell cycle, which consists of phases (G1, S, G2, and M). Cancer cells often bypass these regulatory mechanisms, leading to uncontrolled proliferation. This can result from mutations in genes that control the cell cycle, such as oncogenes (which promote cell division) and tumor suppressor genes (which inhibit cell division). |
| 4734- | SeNPs, | CPT-11, | Cytotoxicity and therapeutic effect of irinotecan combined with selenium nanoparticles |
| - | in-vitro, | CRC, | HCT8 | - | in-vivo, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:380 Target#:323 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid